Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight
1 other identifier
observational
292
1 country
1
Brief Summary
Alkaline phosphatase is known to be produced by syncytiotrophoblasts in the placenta and its levels are normally increased in pregnancy. Therefore, it would be reasonable to hypothesize that alkaline phosphatase would be low to low normal in cases of low birth weight / intrauterine growth restriction (IUGR)/ placental insufficiency.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 13, 2017
CompletedStudy Start
First participant enrolled
June 14, 2017
CompletedFirst Posted
Study publicly available on registry
June 15, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 5, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 5, 2019
CompletedAugust 28, 2019
August 1, 2019
2.1 years
June 13, 2017
August 26, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Birth Weight at Delivery
Birth Weight at Delivery
At Delivery
Study Arms (1)
Pregnant women at 24-28 weeks gestation
Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
Interventions
Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
Eligibility Criteria
Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.
You may qualify if:
- Patients enrolled between 24w0d and 28w6d weeks gestational age will be included. The blood specimen of the patients enrolled will be held until delivery.
You may not qualify if:
- Multiple gestations
- Known congenital malformations (any, except Pyelectasis)
- Chronic hypertension
- Inflammatory bowel disease (IBD)
- Gall bladder disease
- Active bone disease (ie, skeletal dysplasia, healing fracture)
- Active liver disease (ie, hepatitis, cholestasis, cholelithiasis (gallstones))
- Pre-existing type 1 and 2 Diabetes
- Early-onset IUGR
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- TriHealth Inc.lead
Study Sites (1)
Good Samaritan TriHealth Hospital
Cincinnati, Ohio, 45220, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Donna Lambers, MD
TriHealth Inc.
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 13, 2017
First Posted
June 15, 2017
Study Start
June 14, 2017
Primary Completion
August 5, 2019
Study Completion
August 5, 2019
Last Updated
August 28, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will not share